Randomized phase II trial of chemoradiotherapy with S-1 versus gemcitabine and S-1 combination therapy as neoadjuvant treatment in patients with resecatble pancreatic cancer
Phase 2
- Conditions
- resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000014894
- Lead Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 103
Inclusion Criteria
Not provided
Exclusion Criteria
1 Treatment history with gemcitabine or fuluoruracil, 2 Use of flucytosine, phenytoin, and warfarin potassium, 3 Fibroid lung or interstitial pneumonia, 4 Pleural lung or ascites 5 Watery diarrhea, etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year progression-free survival
- Secondary Outcome Measures
Name Time Method overall survaival (2-year survival rate), R0 or 1 resection rate, pathological response rate, adverse event of neoadjuvant therapy, morbidity rate of surgery, non-hematologic adverse event of grade 4, early mortality rate, treatment-related mortality rate